Figure 10. BCL2A1 was an independent predictor of response to temozolomide in gliomas. (A) BCL2A1 expression in gliomas with methylated or unmethylated MGMT promoters. (B) The correlation between BCL2A1 and MGMT expression in public datasets. (C, D) Effect of BCL2A1 on the prognosis of patients with GBM and LGG with different MGMT promoter methylation statuses. (E, F) Effect of BCL2A1 on the prognosis of glioma patients who received TMZ chemotherapy or IR alone. Abbreviations: IR: ion radiotherapy; ns: non-significant. *P < 0.05, **P < 0.01. ***P < 0.001, ****P < 0.0001.